Home | Log In | Register | Our Services | My Account | Contact | Help |
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Tuesday 13 February 2018
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:18.00 | Registration and coffee | |
18.30 | Presentations • Dave Mutton, COO - PrimaryBid • Stewart MacDonald, CFO - Rockhopper Exploration (RKH) • Dr. Satu Vainikka, CEO - Valirx (VAL) + More to be announced | |
20.30 | Drinks reception and canapés | |
21.30 | Close |
![]() | PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges. Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares. Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment. To date over £52m has been sourced via the platform. |
![]() | Rockhopper Exploration plc ("Rockhopper") is an AIM listed oil and gas exploration company based in the UK with interests in the Falkland Islands. It was established in 2004 with a strategy to invest in and undertake an offshore oil exploration programme. It was floated on AIM in August 2005. Rockhopper holds 40% interests in production licences PL032 and PL033 and, on completion of a farm-in announced in October 2013, 24% stakes in blocks PL004a, PL004b, and PL004c. All of these blocks are operated by Premier Oil. In addition, it has a 3% interest block PL003, operated by Falkland Oil and Gas. In August 2014 Rockhopper completed the takeover of Mediterranean Oil & Gas plc ("MOG"). Through the acquisition of MOG, Rockhopper now holds a portfolio of production, development/appraisal and exploration interests in Italy, Malta and France. |
![]() | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |